HORSHAM, Pa., Oct. 19 /PRNewswire/ -- Teva Respiratory announced today the launch of EIB Active, a national health campaign to raise awareness about exercise-induced bronchospasm, or EIB, a condition that impacts an estimated 30 million people in the United States. EIB is a treatable condition that causes wheezing, coughing and chest tightness during or immediately following exercise or physical activity.
Despite the large number of people living with EIB, diagnosis remains low due to a lack of awareness and understanding about EIB as a distinct condition. Although exercise is often the most common cause of asthma symptoms, the shortness of breath, wheezing, coughing, chest tightness, unusual fatigue or trouble getting a deep breath that many may experience during exercise may actually be EIB, which affects both children and adults with asthma, and the general population.
Led by Jo Frost, celebrity nanny and parenting expert, and a team of professionals, including coaches, athletes and physicians, EIB Active aims to educate school nurses, teachers, coaches, parents and children about the signs and symptoms of EIB to ensure identification and treatment of this manageable condition through a series of local market events.
"I'm teaming up with Teva Respiratory and EIB Active because it's important for me to educate people about EIB, so that if they are experiencing symptoms, which may lead them to stop exercising or participating in sports, they need to speak with a physician," says Jo Frost, celebrity nanny and parenting expert. "It's important for those who have EIB and/or asthma, like myself, to effectively manage it so they can stay healthy and active."
The campaign offers children and families information, resources and updates through www.EIBActive.com. Parents and kids can find interactive content, including an EIB screener, educational information and insights into the life of Jo Frost. The campaign aims to educate about the importance of proper treatment to effectively manage EIB symptoms in both patients diagnosed with asthma and those experiencing breathing problems who do not have asthma.
EIB is sometimes referred to as exercise-induced asthma, because the symptoms of EIB are similar to the symptoms of asthma; however, EIB symptoms are only present during or immediately following exercise or physical activity. An estimated nine out of ten (80-90%) children and adults with asthma have EIB. Additionally, there are people who do not have asthma who experience symptoms only during exercise. EIB occurs in approximately one out of ten (10%) individuals among the general population who do not have a known history of chronic asthma. These symptoms can have a significant impact on participation in exercise and in some instances, may be the reason children and adults avoid exercise or being active altogether. In general, lack of exercise can lead to weight gain and obesity, which are risk factors for heart disease, high blood pressure, diabetes and trouble sleeping.
Treatment for Exercise-Induced Bronchospasm
According to the NHLBI-NAEPP guidelines, EIB can be prevented by using a short-acting beta-agonist (SABA), such as albuterol 15 to 30 minutes prior to vigorous activity or exercise. Survey results from EIB: A Landmark Survey found SABAs were most often cited by physicians as the class of medication with the highest therapeutic yield for adults and children with exercise-related symptoms.
ProAir® HFA (albuterol sulfate) Inhalation Aerosol is a safe and effective treatment option for EIB to help people prevent their EIB symptoms from occurring. ProAir® HFA is a quick-relief inhaler designed to be carried and stored in any position for the active, on-the-go, lifestyle. Used 15 to 30 minutes before exercise, ProAir® HFA quickly opens up the airways in the lungs, preventing EIB symptoms from occurring in the first place.
On average, 74% of healthcare providers surveyed in EIB: A Landmark Survey agreed quick-relief inhalers should be used prior to exercise. Interestingly, the survey revealed that only 29% of asthma patients with undiagnosed EIB were aware that SABAs should be used before exercise. Within this population, the survey found these patients are far more likely to use their quick-relief inhaler after they exercise (45%). Even those asthma patients who have been diagnosed with EIB are not always using their inhaler as recommended by NHLBI-NAEPP – 43% use a SABA before exercise, while 47% use their inhaler after exercise.
While pre-treatment with a SABA is what doctors recommend for managing EIB symptoms, asthmatic patients who have frequent, severe EIB should talk to their physician to evaluate the status of their condition. There may be a need to initiate or increase daily long-term control therapy since symptoms of EIB for those with asthma can be a sign that their asthma is not well controlled.
About EIB: A Landmark Survey
Exercise-Induced Bronchospasm "(EIB): A Landmark Survey" is the first comprehensive national survey of the public, asthma patients and healthcare providers about exercise-related respiratory symptoms in the U.S. The survey included more than 3,000 interviews conducted between December 2009 and February 2010. A national sample of 1,001 adults and 516 children, aged 4 and older, who have been diagnosed with asthma and who have had asthma symptoms in the past 12 months or are taking medicine for their asthma, was interviewed by telephone about their condition and treatment. For comparison, a national sample of 1,085 adults was also interviewed. In addition, a national sample of 450 healthcare providers were interviewed as part of this survey to provide insights on the healthcare provider perspective of asthma management. "EIB: A Landmark Survey" was conducted by national public opinion research organization Abt SRBI Inc. in partnership with Strategic Pharma Solutions LLC and sponsored by Teva Respiratory.
About Asthma and Exercise-Induced Bronchospasm
Asthma is a chronic (long-term), treatable lung disease that causes inflammation and constriction of smooth muscle around the large and small airways (or bronchial tubes). When something sets off or triggers an asthma attack, like exercise, airways become inflamed and swollen, and the muscles around the airways tighten (bronchospasm). Symptoms of asthma include wheezing (a whistling sound when you breathe), chest tightness, shortness of breath and coughing that often occurs at night or early in the morning. Without appropriate treatment, asthma symptoms may become more severe and result in an asthma attack, which can lead to hospitalization and even death. If a person has EIB, physical exertion may be the only thing that triggers asthma symptoms.
Asthma affects people of all ages, but it most often starts in childhood. In the U.S., more than 22 million people are known to have asthma, including more than 6 million children. Each year in the U.S., asthma causes approximately 500,000 hospitalizations, 134 million days of restricted activity and 5,000 deaths. It is estimated that 80 to 90 percent of all individuals who have asthma will experience symptoms of EIB with vigorous exercise or activity.
About ProAir® HFA (albuterol sulfate) Inhalation Aerosol
ProAir® HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Important Safety Information
If your symptoms become significantly worse when you use ProAir® HFA, contact your doctor immediately. This may indicate either a worsening of your asthma or a reaction to the medication, which may rarely occur with the first use of a new canister of ProAir® HFA. Either of these could be life-threatening.
What to tell your doctor before using ProAir® HFA: If you have a heart, blood, or seizure disorder, high blood pressure, diabetes, or an overactive thyroid, be sure to tell your doctor. Also make sure your doctor knows all the medications you are taking – especially heart medications and drugs that treat depression – because some medications may interfere with how well your asthma medications work. Do not exceed the recommended dose.
Side effects associated with ProAir® HFA (albuterol sulfate) Inhalation Aerosol included headache, rapid heart beat, pain, dizziness, and irritation of the throat and nose.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full prescribing information at http://www.proairhfa.com/pdf/ProAirPrescribingInformation.pdf. For a printed copy, please see the full prescribing information.
About Teva Respiratory
Teva Respiratory is the U.S.-based respiratory subsidiary of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Europe.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin®, Lotrel®, Protonix® and Yaz®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of ratiopharm), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission ("SEC").
SOURCE: Teva Respiratory, LLC is a subsidiary of Teva Pharmaceutical Industries Ltd.
ProAir® HFA is a registered trademark of Teva Respiratory, LLC. EIB Active™ is a trademark of Teva Respiratory, LLC. ©2010, Teva Respiratory. All Rights Reserved.
SOURCE Teva Respiratory